Posted on: Mon, Jun 2019

Success Story: Hosea Zedex Votapwa from New Life Gospel Centre (Our Father’s House, Demsawo Community, Yola, Adamawa State North-East Zone

My name is Hosea Zedex Votapwa from New Life Gospel Centre (Our Father’s House), Demsawo Community, Yola, Adamawa State. I attended the CRUDAN capacity building workshop for youths on Integrated Waste Management held at Lutheran Church of Christ in Nigeria from 12-14 December, 2017

Before the workshop, I had little or no knowledge that nothing good can come out from waste. Waste clothes/ jeans were either thrown out or burned.

But after attending the CRUDAN workshop on Integrated Waste Management, I realized that I have thousands of naira littered in and around my compound and neighborhood in form of waste. With the knowledge acquired from the workshop, I decided to look at how to turned the waste into wealth.  I collected the waste Clothes/and Jeans in my house and around my compound and with my skills as a shoe designer, I produce foot wears from the worn-out clothes/jean material. I succeeded in making and producing two pairs of shoes which were sold out at the rate of one thousand (N1000) and two thousand five hundred Naira (N2,500) respectively. The Hausa has a saying that “he who lives by the well or river side should never complain of being thirsty.”

I learnt that waste is never a menace to the community depending on how well it is managed. If managed properly, it can promote circular economy thereby stabilizing the economy.

During the process, I was faced with the challenge of mockery from my mother and my boss at work. When my mother saw me gathering the waste clothes, she said; “something is definitely wrong with your brains, what do you want to do with trash of waste you are gathering and bringing into my compound”. My boss on the other hand, said “you are very sick” he said I was wasting money in buying gum and other materials.


After producing the shoes, my mother and my boss really appreciated my effort and asked me to forgive them for the mockery they have made and asked me to keep it up. The members of my community also commended my effort for such creativity. They have now resorted to storing worn-out cloths for me to make some nice foot wear out of it. Some neighbors have offered to sell out the shoes whenever they are produced. A chain and synergy of business is about to surface. My thanks to CRUDAN for building my capacity. “Our trash is fast turning into cash!!”

Hosea Zedex Votapwa

Demsawo Community, Yola Nigeria :09095760025

Community Support: FREE MILLING.

Posted on: Sun, Jun 2019

Amazing, cost of milling is totally free, but he makes money by selling the chaff which customers leave behind.

Mr. Temitayo Omole, EU Delegate, Mr. Constant Tchona, Oxfam Nigeria Interim Country Director with Ruth Dul, CRUDAN Executive Director and  Polina Rak, Oxfam Grant Manager from Oxford , interacting with one of the beneficiary of milling machine  in Dirbishi Community of Mubi south LGA. The beneficiary  expressed gratitude to EU ,Oxfam and CRUDAN  for their great support . He further mentioned how milling  is done for free in exchange for the chaff which eventually is sold for the purpose of feeding their livestocks. In addition he said, amount generated  from the sales of chaffs is able to pay the salaries of two of his employees and also covers other overhead cost.

CRUDAN is working to reduce poverty in Adamawa State.

Posted on: Mon, Jun 2019

One of the PROACT Project Beneficiaries.

The woman is one of the PROACT Project Beneficiaries. She initially started business with two cows but now has six cows each is around N120, 000. This is a great impact! CRUDAN is working to reduce poverty in Adamawa State.

Malaria vaccine pilot launched in Malawi

Posted on: Thu, Jul 2019

Country first of three in Africa to roll out landmark vaccine

Malaria remains one of the world’s leading killers, claiming the life of one child every two minutes. Most of these deaths are in Africa, where more than 250 000 children die from the disease every year. Children under 5 are at greatest risk of its life-threatening complications. Worldwide, malaria kills 435 000 people a year, most of them children.

WHO welcomes the Government of Malawi’s launch of the world’s first malaria vaccine today in a landmark pilot programme. The country is the first of three in Africa in which the vaccine, known as RTS,S, will be made available to children up to 2 years of age; Ghana and Kenya will introduce the vaccine in the coming weeks.

“We have seen tremendous gains from bed nets and other measures to control malaria in the last 15 years, but progress has stalled and even reversed in some areas. We need new solutions to get the malaria response back on track, and this vaccine gives us a promising tool to get there,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “The malaria vaccine has the potential to save tens of thousands of children’s lives.”

An innovation milestone, three decades in development

Thirty years in the making, RTS,S is the first, and to date the only, vaccine that has demonstrated it can significantly reduce malaria in children. In clinical trials, the vaccine was found to prevent approximately 4 in 10 malaria cases, including 3 in 10 cases of life-threatening severe malaria

“Malaria is a constant threat in the African communities where this vaccine will be given. The poorest children suffer the most and are at highest risk of death,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We know the power of vaccines to prevent killer diseases and reach children, including those who may not have immediate access to the doctors, nurses and health facilities they need to save them when severe illness comes.”

“This is a day to celebrate as we begin to learn more about what this tool can do to change the trajectory of malaria through childhood vaccination,” she added.

The pilot programme is designed to generate evidence and experience to inform WHO policy recommendations on the broader use of the RTS,S malaria vaccine. It will look at reductions in child deaths; vaccine uptake, including whether parents bring their children on time for the four required doses; and vaccine safety in the context of routine use.

The vaccine is a complementary malaria control tool – to be added to the core package of WHO-recommended measures for malaria prevention, including the routine use of insecticide-treated bed nets, indoor spraying with insecticides, and the timely use of malaria testing and treatment.

A model public-private partnership

The WHO-coordinated pilot programme is a collaborative effort with ministries of health in Ghana, Kenya and Malawi and a range of in-country and international partners, including PATH, a non-profit organization, and GSK, the vaccine developer and manufacturer, which is donating up to 10 million vaccine doses for this pilot.

“We salute WHO and Malawi for their leadership in realizing this historic milestone,” said Steve Davis, President and CEO of PATH, “and we look forward to the start of vaccination in Ghana, and then Kenya later this year. A vaccine for malaria is among many innovations needed to bring an end to this disease, and we proudly stand with all countries and our many partners in progressing towards a malaria-free world.”

The malaria vaccine pilot aims to reach about 360,000 children per year across the three countries. Ministries of health will determine where the vaccine will be given; they will focus on areas with moderate-to-high malaria transmission, where the vaccine can have the greatest impact.

“Delivering the world’s first malaria vaccine will help reduce the burden of one of the most pressing health challenges globally. This novel tool is the result of GSK employees collaborating with their partners, applying the latest in vaccine science to contribute to the fight against malaria,” said Dr Thomas Breuer, Chief Medical Officer of GSK Vaccines. “We look forward to seeing the results of the pilot, and in parallel, are working with WHO and PATH to secure the vaccine’s sustained global health impact in the future.”

Financing and support

Financing for the pilot programme has been mobilized through an unprecedented collaboration among three key global health funding bodies: Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and Unitaid. Additionally, WHO, PATH and GSK are providing in-kind contributions.

Notes to the editors:

  • Pilot countries: Following a request by WHO for expressions of interest, the pilot countries were selected from among 10 African countries. Key criteria for selection included well-functioning malaria and immunization programmes, and areas with moderate to high malaria transmission. 
  • Proven results: In Phase 3 trials conducted in Africa, between 2009 and 2014, children receiving 4 doses of RTS,S experienced significant reductions in malaria and malaria-related complications, in comparison to those who did not receive RTS,S. The vaccine prevented 4 in 10 cases of clinical malaria; 3 in 10 cases of severe malaria; and 6 in 10 cases of severe malaria anaemia, the most common reason children die from malaria. Significant reductions were also seen in overall hospital admissions and the need for blood transfusions, which are required to treat severe malaria anaemia. These and other benefits were in addition to those already seen through the use of insecticide-treated nets (bed nets); prompt diagnosis; and effective antimalarial treatment.
  • Child vaccination schedule: In selected areas in the three countries, the vaccine will be given in 4 doses: 3 doses between 5 and 9 months of age and the fourth dose provided around the 2nd birthday.


Posted on: Fri, Nov 2019


Over the years, CRUDAN’s experience in humanitarian response was limited. However, when armed conflict broke out in northern Nigeria, both CRUDAN and Tearfund wanted to respond to the emergency needs of the communities affected. So they found a new way of working together – Tearfund would support CRUDAN to strengthen its humanitarian response capacity. 


Leave a comment